Clinical trial
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal…
NCT00293527 · Ohio State University Comprehensive Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00293527 |
|---|---|
| Title | Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma |
| Official title | A Phase II Dose Escalation Study of Continuous Daily Subcutaneous Administration of Interferon Alpha-2b in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cancer |
| Intervention type | Drug |
| Interventions | Interferon Alpha-2b |
| Enrollment | 0 |
| Completion | Nov 1, 2006 |
| First posted | Feb 17, 2006 |
| Last update posted | May 23, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: